Research in this project is currently focused on three areas. These are characterization of the survivors of the anthrax attacks of 2001;characterization of emerging respiratory infections including SARS and influenza;and development of novel therapies for flu. The anthrax study has enrolled a cohort of volunteers who are currently undergoing an extensive diagnostic evaluation. To be ready to deal with emerging infectious diseases of the respiratory tract, a protocol has been developed to systematically study patients presenting with a compatible symptom complex. This protocol has been complemented by the development of treatment protocols that will utilize hyperimmune plasma to the 2009 H1N1 virus or a combination of antiviral chemotherapeutic agents.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2013
Total Cost
$191,279
Indirect Cost
City
State
Country
Zip Code
Lynfield, Ruth; Davey, Richard; Dwyer, Dominic E et al. (2014) Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies. PLoS One 9:e101785
Beigel, John H; Voell, Jocelyn; Huang, Chiung-yu et al. (2009) Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis 200:501-9